Nrx pharmaceuticals (nasdaq:nrxp) announces publication of paper entitled "quality assurance of depression ratings in psychiatric clinical trials"

Nrx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of nrx-101 documents higher interrater reliability (irr) on primary endpoint (madrs depression scale) than previously reported industry standards positive implications for conduct of future registration trials for nrx-101 and similar medications. published in the peer reviewed american journal of clinical psychopharmacology wilmington, del.
NRXP Ratings Summary
NRXP Quant Ranking